These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6580896)

  • 41. Common drugs of abuse--Part II.
    Cuddy ML
    J Pract Nurs; 2004; 54(1):5-8, 25-31; quiz 17-9. PubMed ID: 15193009
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Age-specific patterns of hallucinogen use in the US population: an analysis using generalized additive models.
    Chilcoat HD; Schütz CG
    Drug Alcohol Depend; 1996 Dec; 43(3):143-53. PubMed ID: 9023070
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Classic hallucinogens in the treatment of addictions.
    Bogenschutz MP; Johnson MW
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():250-8. PubMed ID: 25784600
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo metabolism of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in the rat: identification of urinary metabolites.
    Kanamori T; Inoue H; Iwata Y; Ohmae Y; Kishi T
    J Anal Toxicol; 2002 Mar; 26(2):61-6. PubMed ID: 11916016
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Conformational energy differences between side chain alkylated analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane.
    Weintraub HJ; Nichols DE; Makriyannis A; Fesik SW
    J Med Chem; 1980 Mar; 23(3):339-41. PubMed ID: 7365752
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Bromo-dragon fly--life-threatening drug. Can cause tissue necrosis as demonstrated by the first described case].
    Thorlacius K; Borna C; Personne M
    Lakartidningen; 2008 Apr 16-22; 105(16):1199-200. PubMed ID: 18522262
    [No Abstract]   [Full Text] [Related]  

  • 47. Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist.
    Benneyworth MA; Smith RL; Sanders-Bush E
    Neuropsychopharmacology; 2008 Aug; 33(9):2206-16. PubMed ID: 17957214
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex.
    Muschamp JW; Regina MJ; Hull EM; Winter JC; Rabin RA
    Brain Res; 2004 Oct; 1023(1):134-40. PubMed ID: 15364028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of 2,5-dimethoxy-4-methylamphetamine (DOM) on operant behavior: interactions with other neuroactive agents.
    Commissaris RL; Semeyn DR; Moore KE; Rech RH
    Commun Psychopharmacol; 1980; 4(5):393-404. PubMed ID: 6120791
    [No Abstract]   [Full Text] [Related]  

  • 50. The hallucinogens and the inhalants.
    Cohen S
    Psychiatr Clin North Am; 1984 Dec; 7(4):681-8. PubMed ID: 6097885
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changing world patterns of drug abuse, 1945-1974.
    Ball JC; Graff H; Chien K
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):109-13. PubMed ID: 1165131
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hallucinogens: an update.
    Halpern JH
    Curr Psychiatry Rep; 2003 Oct; 5(5):347-54. PubMed ID: 13678554
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intraventricular injections of galanin counteract development of head twitches induced by the 5-HT-2 agonist 1-(2,5-dimethoxyphenyl-4-bromo)-2-aminopropane.
    Ogren SO; Fuxe K
    Acta Physiol Scand; 1989 Jun; 136(2):297-8. PubMed ID: 2476910
    [No Abstract]   [Full Text] [Related]  

  • 54. (R)-(-)-[77Br]4-bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes.
    Peroutka SJ; Hamik A; Harrington MA; Hoffman AJ; Mathis CA; Pierce PA; Wang SS
    Mol Pharmacol; 1988 Oct; 34(4):537-42. PubMed ID: 3173334
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Conservative treatment of jimsonweed ingestion.
    Rodgers GC; Von Kanel RL
    Vet Hum Toxicol; 1993 Feb; 35(1):32-3. PubMed ID: 8434447
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The present status of drug dependence in Australia.
    Bell DS
    Addict Dis; 1977; 3(1):115-8. PubMed ID: 930685
    [No Abstract]   [Full Text] [Related]  

  • 57. Effects of clozapine and 2,5-dimethoxy-4-methylamphetamine [DOM] on 5-HT2A receptor expression in discrete brain areas.
    Doat-Meyerhoefer MM; Hard R; Winter JC; Rabin RA
    Pharmacol Biochem Behav; 2005 Aug; 81(4):750-7. PubMed ID: 15972234
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of dependence upon stimulants and hallucinogens.
    Tennant FS
    Drug Alcohol Depend; 1983 Feb; 11(1):111-4. PubMed ID: 6851847
    [No Abstract]   [Full Text] [Related]  

  • 59. Associations between individual hallucinogens and hallucinogen misuse among U.S. Adults who recently initiated hallucinogen use.
    Jones G; Herrmann F; Wang E
    Addict Behav Rep; 2023 Dec; 18():100513. PubMed ID: 37649653
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hallucinogen Persisting Perception Disorder and Risk of Suicide.
    Brodrick J; Mitchell BG
    J Pharm Pract; 2016 Aug; 29(4):431-4. PubMed ID: 25631475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.